AbbVie Says It Can't Confirm Reports About Efficacy Of Drug In Treating Coronavirus
March 09 2020 - 9:54AM
Dow Jones News
By Micah Maidenberg
AbbVie Inc. said it can't confirm reports about the efficacy of
one of its therapies in treating people with the coronavirus.
Media reports in China have said that an AbbVie drug designed
for HIV patients is effective in treating Covid-19, the disease
that the coronavirus cases, AbbVie said Monday.
"AbbVie does not have access to Chinese clinical information and
therefore cannot confirm its accuracy," the company said.
The drug, marketed as Kaletra or Aluvia, contains two protease
inhibitors, lopinavir and ritonavir, according to the company.
AbbVie said it had supplied Kaletra or Aluvia as an experimental
option to treat people with the coronavirus to multiple countries
and has seen higher demand for the drug. The Chinese government was
among the recipients of Aluvia.
"While helping respond to the Covid-19 crisis is a high
priority, the company is committed to protecting the supply of
Kaletra/Aluvia for HIV patients," AbbVie said.
Share of North Chicago, Ill.-based AbbVie fell 6.2%
premarket.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
March 09, 2020 09:39 ET (13:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024
